Broader Cancer Risk With CAR-T? AI for Physician Burnout; ‘Lollipops’ ID Oral Cancer

T-cell malignancies represent a small fraction of secondary cancers in patients treated with CAR T-cell therapy. (American Society of Hematology)

In an update to a clinical guideline, the American Society of Clinical Oncology has recommended capivasertib (Truqap) plus fulvestrant for hormone receptor-positive/HER2-negative metastatic breast cancer with PIK3CA or AKT1 mutations or PTEN inactivation.

Cloud-based software company Salesforce announced the rollout of Einstein Copilot: Health Actions, the first of several AI solutions that will automate many of the administrative duties that drive physician burnout. (CNBC)

The 2024 version of #FierceMadness, coinciding with the NCAA’s “March Madness” basketball tournament, challenges readers to choose the best drug name among recent FDA approvals. (FiercePharma)

A recently discovered bacterium has two subspecies, one of which appears to shield colon cancer cells from treatments. (NBC News, Nature)

The FDA announced full approval of mirvetuximab soravtansine (Elahere) for previously treated folate receptor-positive, platinum-resistant ovarian cancer.

Older patients with acute myeloid leukemia live longer than ever with stem cell transplants. (American Association for Cancer Research)

Many publicly available artificial intelligence programs and apps lack adequate safeguards to prevent mass generation of health misinformation. (The BMJ)

Hydrogel “lollipops” have shown early promise for diagnosing oral cancers. (University of Birmingham, BBC)

Bristol Myers Squibb announced that the immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival in advanced liver cancer as compared with targeted therapy.

Electroencephalography showed promising for helping at least some patients avoid MRI and lumbar puncture to diagnose and manage neurologic complications of CAR T-cell therapy. (American Society of Hematology)

Merck announced that a phase III trial in metastatic non-small cell lung cancer showed no improvement in survival with pembrolizumab (Keytruda) plus maintenance therapy with olaparib (Lynparza).

Please enable JavaScript to view the

comments powered by Disqus.